Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon <scp> <i>EGFR</i> </scp> mutations: Real‐world data from Taiwan-Reference-Cited by-同舟云学术

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

Published:2022-11-24 Issue:1 Volume:14 Page:12-23
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Chang John Wen‐Cheng¹,Huang Chen‐Yang¹,Fang Yueh‐Fu²,Chang Ching‐Fu¹,Yang Cheng‐Ta²,Kuo Chih‐Hsi Scott²,Hsu Ping‐Chih²,Wu Chiao‐En¹^ORCID

Affiliation:

1. Division of Hematology‐Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou Chang Gung University College of Medicine Taoyuan Taiwan

2. Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou Chang Gung University College of Medicine Taoyuan Taiwan

Funder

Chang Gung Memorial Hospital, Linkou

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14537

Reference28 articles.

1. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial